Sprint Bioscience
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
SPRINT | ST
Overview
Corporate Details
- ISIN(s):
- SE0006343745
- LEI:
- 5493006ED74WIIQOKC56
- Country:
- Sweden
- Address:
- C/O NOVUM, 141 57 Huddinge
- Website:
- https://sprintbioscience.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Sprint Bioscience is a pharmaceutical company specializing in early-phase drug development within oncology. The company utilizes a fragment-based drug discovery (FBDD) platform to identify and develop innovative, preclinical drug candidates for difficult-to-treat cancers. Its business model is centered on advancing these programs in a time- and resource-efficient manner before out-licensing them to global pharmaceutical partners for continued clinical development and eventual commercialization. This strategy focuses on creating high-value oncology assets to address significant unmet needs in cancer treatment.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all Sprint Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sprint Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sprint Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
